Baseline characteristics of study patients (n = 51). Values are mean (SD) unless otherwise specified.
| Variable | Values |
|---|---|
| Age at end of extension study, yrs | 53.8 (11.9) |
| Female, n (%) | 41 (80.4) |
| Race, n (%) | |
| White | 46 (90.2) |
| Black | 5 (9.8) |
| SSc subtype, n (%) | |
| Limited | 43 (84.3) |
| Diffuse | 8 (15.7) |
| SSc duration at end of extension, yrs | 12.3 (9.1) |
| Autoantibody type, no. positive/total tested | |
| Centromere | 22/45 |
| Topoisomerase 1 | 11/39 |
| Active drug assignment in original clinical trial, n (%) | 26 (51) |
| Length of time receiving drug in extension study, days | 340 (120.5) |
| Treprostinil dose, mg/day | 5.7 (3.87) |
| Calcium channel blocker use at end of extension, n (%) | 29 (56.9) |
| SHAQ Raynaud score at end of extension* | 0.5 (0.65) |
| SHAQ Disability Index at end of extension* | 0.7 (0.5) |
↵* N = 50. SSc: systemic sclerosis; SHAQ: Scleroderma Health Assessment Questionnaire.